Connection

YA-CHEN TINA SHIH to Cost-Benefit Analysis

This is a "connection" page, showing publications YA-CHEN TINA SHIH has written about Cost-Benefit Analysis.
Connection Strength

5.686
  1. Cost-effectiveness of medication therapy management among Medicare population and across racial/ethnic groups. Medicine (Baltimore). 2024 May 03; 103(18):e37935.
    View in: PubMed
    Score: 0.683
  2. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer : A Cost-Effectiveness Analysis. Ann Intern Med. 2021 05; 174(5):602-612.
    View in: PubMed
    Score: 0.546
  3. Use of Claims Data for Cost and Cost-Effectiveness Research. Semin Radiat Oncol. 2019 10; 29(4):348-353.
    View in: PubMed
    Score: 0.497
  4. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019 Aug; 6(8):e398-e408.
    View in: PubMed
    Score: 0.487
  5. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women. Value Health. 2019 02; 22(2):185-193.
    View in: PubMed
    Score: 0.462
  6. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462.
    View in: PubMed
    Score: 0.425
  7. Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan. Pharmacoeconomics. 2009; 27(11):947-61.
    View in: PubMed
    Score: 0.236
  8. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics. 2007; 25(7):577-90.
    View in: PubMed
    Score: 0.205
  9. Impact of generic drug entry on cost-effectiveness analysis. Med Decis Making. 2005 Jan-Feb; 25(1):71-80.
    View in: PubMed
    Score: 0.179
  10. The utility of value frameworks in cost communications: making them real for patients. J Natl Cancer Inst. 2024 Sep 01; 116(9):1411-1413.
    View in: PubMed
    Score: 0.175
  11. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention. JAMA Netw Open. 2024 02 05; 7(2):e2356078.
    View in: PubMed
    Score: 0.168
  12. A Systematic?Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics. 2021 11; 39(11):1271-1297.
    View in: PubMed
    Score: 0.141
  13. Time to Consider a Personalized Approach to Incorporate Tomosynthesis Into Routine Breast Cancer Screening. J Natl Cancer Inst. 2020 06 01; 112(6):553-554.
    View in: PubMed
    Score: 0.130
  14. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. Pharmacoeconomics. 2019 03; 37(3):301-331.
    View in: PubMed
    Score: 0.119
  15. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 Jul; 35(7):685-695.
    View in: PubMed
    Score: 0.106
  16. Cost-Effectiveness Analysis of a Capitated Patient Navigation Program for Medicare Beneficiaries with Lung Cancer. Health Serv Res. 2016 Apr; 51(2):746-67.
    View in: PubMed
    Score: 0.092
  17. Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer. 2014 Oct 14; 111(8):1542-51.
    View in: PubMed
    Score: 0.087
  18. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics. 2014 Jul; 32(7):651-80.
    View in: PubMed
    Score: 0.086
  19. Preparing for an epidemic: cancer care in an aging population. Am Soc Clin Oncol Educ Book. 2014; 133-7.
    View in: PubMed
    Score: 0.083
  20. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014; 10(11):3415-24.
    View in: PubMed
    Score: 0.083
  21. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb; 14(1):45-69.
    View in: PubMed
    Score: 0.083
  22. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health. 2012 Mar-Apr; 15(2):367-75.
    View in: PubMed
    Score: 0.072
  23. Economic burden of renal cell carcinoma: Part I--an updated review. Pharmacoeconomics. 2011 Apr; 29(4):315-29.
    View in: PubMed
    Score: 0.069
  24. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin. 2008 Jul-Aug; 58(4):231-44.
    View in: PubMed
    Score: 0.057
  25. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients. Pharmacoeconomics. 2007; 25(10):843-62.
    View in: PubMed
    Score: 0.051
  26. Do pharmacogenomic tests provide value to policy makers? Pharmacoeconomics. 2006; 24(12):1173-7.
    View in: PubMed
    Score: 0.048
  27. Examining the Association between Abstinence from Smoking and Healthcare Costs among Patients with Cancer. Cancer Prev Res (Phila). 2024 May 02; 17(5):217-225.
    View in: PubMed
    Score: 0.043
  28. The economic burden of supportive care of cancer patients. Support Care Cancer. 2004 Apr; 12(4):219-26.
    View in: PubMed
    Score: 0.042
  29. Methods and Study Design for Cancer Health Economics Research: Summary of Discussions From a Breakout Session. J Natl Cancer Inst Monogr. 2022 07 05; 2022(59):95-101.
    View in: PubMed
    Score: 0.038
  30. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform. 2019 03; 3:1-12.
    View in: PubMed
    Score: 0.030
  31. How much of US health care spending provides direct care or benefit to patients? Cancer. 2019 05 01; 125(9):1404-1409.
    View in: PubMed
    Score: 0.030
  32. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532.
    View in: PubMed
    Score: 0.029
  33. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007 Aug 01; 110(3):678-85.
    View in: PubMed
    Score: 0.027
  34. Favorable Cardiovascular Health, Compression of Morbidity, and Healthcare Costs: Forty-Year Follow-Up of the CHA Study (Chicago Heart Association Detection Project in Industry). Circulation. 2017 May 02; 135(18):1693-1701.
    View in: PubMed
    Score: 0.026
  35. The cost-effectiveness of a trial of labor accrues with multiple subsequent vaginal deliveries. Am J Obstet Gynecol. 2014 Jul; 211(1):56.e1-56.e12.
    View in: PubMed
    Score: 0.021
  36. Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol. 2010 Nov-Dec; 8(6):242-51.
    View in: PubMed
    Score: 0.017
  37. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer. 2004 Jul; 12(7):531-6.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.